Signed in as:
filler@godaddy.com
About Us
BSTM Device
The BSTM™ Device is a simple ‘Petri Dish for Biofilms’ that allows for high-throughput screening of different surfaces. It provides a universally acceptable high-throughput format (in 6, 12, and 24 well tissue culture plates) that allows for the interchange of customizable surfaces of interest (including hard surfaces for disinfection, novel materials, medical devices, ship hull samples, etc.).
NOTE: We currently are only able to offer custom made BSTM Devices and custom manufacturing instructions at this time. We are currently working through the design and build out of the consumer ready product. Please contact us for more information.
BSTM Lab
Researchers at Chinook Contract Research (CCR) Inc. www.ccr01.com (a small Canadian company specializing in biofilm research) have been serving clients (which include government, military, academia, consumer products, medical device and pharmaceutical manufacturers) for over 10 years, supporting their research into effective antibiofilm treatments, medical devices, and surface treatments. A universal concern of these varied industries is a lack of a practical research tool and an internationally recognized standard to support their research claims. To this end, our research team has developed a simple, high-throughput, biofilm surface research tool to meet this need: the Biofilm Surface Test Method (BSTM™) Device.
Biofilms
Biofilm is a complex structure of microbes comprised of different bacterial colonies or a single type of cells in a group; these adhere to a surface (Sharma, Misba, & Khan, 2019) and are a serious global health concern due to their abilities to tolerate antibiotics, host defense systems, and other external stresses, thus contributing to persistent, chronic infections (Costerton JW, 1999) (Allan, Giare-Patel, & Olson, 2012).
Consequently, the biofilm treatment market, in terms of revenue, was estimated to be worth $1.6 billion in 2020 and is poised to reach $2.4 billion by 2025, growing at a CAGR of 7.9% (2023). Research into biofilm treatments and novel medical devices and surfaces is expected to grow to meet this market demand. Currently, this research is severely limited by a lack of a readily available standard test method that is both recognized by the regulatory community (i.e. Health Canada and USFDA) and easily implementable by the research community. This project seeks to address this gap.